L. P. Bloss

486 total citations
23 papers, 358 citations indexed

About

L. P. Bloss is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, L. P. Bloss has authored 23 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in L. P. Bloss's work include Lung Cancer Treatments and Mutations (10 papers), Occupational and environmental lung diseases (9 papers) and Pleural and Pulmonary Diseases (7 papers). L. P. Bloss is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Occupational and environmental lung diseases (9 papers) and Pleural and Pulmonary Diseases (7 papers). L. P. Bloss collaborates with scholars based in United States. L. P. Bloss's co-authors include Jeffrey D. Bloss, Scott McMeekin, Alberto Manetta, Philip J. DiSaia, Richard E. Buller, Michael L. Berman, Shu‐Yuan Liao, Coleman K. Obasaju, Matthew Monberg and Rafael E. Curiel and has published in prestigious journals such as Journal of Clinical Oncology, Gynecologic Oncology and Journal of Thoracic Oncology.

In The Last Decade

L. P. Bloss

23 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. P. Bloss United States	8	219	119	116	114	70	23	358
Kara Judson United States	7	241 1.1×	127 1.1×	113 1.0×	56 0.5×	45 0.6×	8	298
M. Heydarfadai Austria	6	223 1.0×	102 0.9×	164 1.4×	90 0.8×	50 0.7×	12	322
William J. Hoskins United States	8	300 1.4×	249 2.1×	294 2.5×	171 1.5×	89 1.3×	8	565
P. Pautier France	9	161 0.7×	73 0.6×	165 1.4×	55 0.5×	79 1.1×	27	325
Webb Mj United States	8	301 1.4×	163 1.4×	135 1.2×	62 0.5×	102 1.5×	14	414
Joan E. Woodward United States	11	188 0.9×	112 0.9×	230 2.0×	54 0.5×	112 1.6×	12	454
M.G. Salerno Italy	12	233 1.1×	147 1.2×	135 1.2×	24 0.2×	93 1.3×	13	334
Susan K. Gibbons United States	7	207 0.9×	119 1.0×	314 2.7×	36 0.3×	49 0.7×	9	368
Donald H. Chamberlain United States	8	161 0.7×	101 0.8×	187 1.6×	61 0.5×	153 2.2×	9	402
M. Amoroso Italy	7	122 0.6×	108 0.9×	216 1.9×	31 0.3×	38 0.5×	14	332

Countries citing papers authored by L. P. Bloss

Since Specialization

Citations

This map shows the geographic impact of L. P. Bloss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. P. Bloss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. P. Bloss more than expected).

Fields of papers citing papers by L. P. Bloss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. P. Bloss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. P. Bloss. The network helps show where L. P. Bloss may publish in the future.

Co-authorship network of co-authors of L. P. Bloss

This figure shows the co-authorship network connecting the top 25 collaborators of L. P. Bloss. A scholar is included among the top collaborators of L. P. Bloss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. P. Bloss. L. P. Bloss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Masters, Gregory A., Athanassios Argiris, Elizabeth A. Hahn, et al.. (2006). A Randomized Phase II Trial Using Two Different Treatment Schedules of Gemcitabine and Carboplatin in Patients with Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 1(1). 19–24. 1 indexed citations

2.

Masters, Gregory A., Athanassios Argiris, Elizabeth A. Hahn, et al.. (2006). A Randomized Phase II Trial Using Two Different Treatment Schedules of Gemcitabine and Carboplatin in Patients with Advanced Non???Small-Cell Lung Cancer. Journal of Thoracic Oncology. 1(1). 19–24. 16 indexed citations

3.

Obasaju, Coleman K., Zhishen Ye, L. P. Bloss, Matthew Monberg, & Rafael E. Curiel. (2005). Gemcitabine/Carboplatin in Patients with Metastatic Non–Small-Cell Lung Cancer: Phase II Study of 28-Day and 21-Day Schedules. Clinical Lung Cancer. 7(3). 202–207. 8 indexed citations

4.

West, Howard, Robert J. Belt, Heather A. Wakelee, et al.. (2005). Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. Journal of Clinical Oncology. 23(16_suppl). 7117–7117. 2 indexed citations

5.

Jänne, Pasi A., George R. Simon, Christiane Langer, et al.. (2005). P-620 An update of pemetrexed (P) plus gemcitabine (G) asfront-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial. Lung Cancer. 49. S282–S282. 1 indexed citations

6.

Jänne, Pasi A., George R. Simon, Corey J. Langer, et al.. (2005). An update of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial. Journal of Clinical Oncology. 23(16_suppl). 7067–7067. 7 indexed citations

7.

Melemed, Allen S., T. A. Larson, Arkadiusz Z. Dudek, et al.. (2005). Final report of a phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors: Second dosing schedule & response. Journal of Clinical Oncology. 23(16_suppl). 7257–7257. 6 indexed citations

8.

Gralla, Richard J., Martin J. Edelman, Frank C. Detterbeck, et al.. (2005). The impact of neoadjuvant chemotherapy and surgery on quality of life (QL) in patients with early stage NSCLC: A prospective analysis of the GINEST project. Journal of Clinical Oncology. 23(16_suppl). 8092–8092. 1 indexed citations

9.

Socinski, Mark A., Frank C. Detterbeck, R. Gralla, et al.. (2005). O-115 Induction chemotherapy with gemcitabine-containing regimensin stage I–II non-small cell lung cancer (NSCLC): Initial results of the GINEST* Project. Lung Cancer. 49. S40–S40. 1 indexed citations

10.

McCleod, Michael, Joseph Treat, Neal P. Christiansen, et al.. (2005). Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial. Journal of Clinical Oncology. 23(16_suppl). 7121–7121. 4 indexed citations

11.

Socinski, Mark A., Lowell L. Hart, J. Thaddeus Beck, et al.. (2005). A randomized phase II trial of pemetrexed (P) plus cisplatin (cis) or carboplatin (carbo) in extensive stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology. 23(16_suppl). 7165–7165. 3 indexed citations

12.

Dudek, Arkadiusz Z., et al.. (2004). A phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2141–2141. 1 indexed citations

13.

Bloss, J., Pasi A. Jänne, Chandra P. Belani, et al.. (2004). Pemetrexed alone or in combination with cisplatin in the treatment of patients with peritoneal mesothelioma (PM): Outcomes of an expanded access program (EAP) in patients with malignant mesothelioma (MM). Journal of Clinical Oncology. 22(14_suppl). 7198–7198. 3 indexed citations

14.

Orlando, Mauro, Pasi A. Jänne, Chandra P. Belani, et al.. (2004). Pemetrexed alone or in combination with cisplatin in previously treated patients with malignant pleural mesothelioma (MPM): Outcomes of an expanded access program (EAP). Journal of Clinical Oncology. 22(14_suppl). 7195–7195. 1 indexed citations

15.

Orlando, Mauro, Pasi A. Jänne, Chandra P. Belani, et al.. (2004). Pemetrexed alone or in combination with cisplatin in previously treated patients with malignant pleural mesothelioma (MPM): Outcomes of an expanded access program (EAP). Journal of Clinical Oncology. 22(14_suppl). 7195–7195. 1 indexed citations

16.

Jänne, Pasi A., Coleman K. Obasaju, George R. Simon, et al.. (2004). A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM). Journal of Clinical Oncology. 22(14_suppl). 7053–7053. 8 indexed citations

17.

Jänne, Pasi A., Coleman K. Obasaju, George R. Simon, et al.. (2004). A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM). Journal of Clinical Oncology. 22(14_suppl). 7053–7053. 5 indexed citations

18.

Bloss, J., S Y Liao, Alberto Manetta, et al.. (1994). Extraovarian peritoneal serous papillary carcinoma: A case‐control retrospective comparison to papillary adenocarcinoma of the ovary. International Journal of Gynecology & Obstetrics. 46(1). 87–87. 19 indexed citations

19.

Bloss, Jeffrey D., Shu‐Yuan Liao, Richard E. Buller, et al.. (1993). Extraovarian Peritoneal Serous Papillary Carcinoma: A Case-Control Retrospective Comparison to Papillary Adenocarcinoma of the Ovary. Gynecologic Oncology. 50(3). 347–351. 183 indexed citations

20.

Bloss, Jeffrey D., et al.. (1991). Use of vaginal hysterectomy for the management of stage I endometrial cancer in the medically compromised patient. Gynecologic Oncology. 40(1). 74–77. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact